Tenderwize
Back to tender search

Open House Discount Agreement Erythropoietin alfa

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 320 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01

60/100

Opportunity Score

PromisingLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

60 / 100

Complexity

20 / 100

Risk factors

No estimated value or volume commitment; actual business may be minimal.

Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive discount agreement for Erythropoietin alfa (ATC B03XA01) with AOK Bayern
  • Supply of pharmaceutical products containing the active substance Erythropoietin alfa
Show full summary

Open house non-exclusive discount agreement for the pharmaceutical product Erythropoietin alfa (ATC B03XA01) with AOK Bayern. All interested pharmaceutical companies meeting eligibility criteria can conclude identical, non-negotiable discount agreements. Contracts run from 1 September 2025 to 31 August 2027, with possible termination. This is not a classic procurement procedure but a non-exclusive open-house model under §130a SGB V. No estimated value is published.

Risks

No estimated value or volume commitment; actual business may be minimal.

Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.

Key Requirements

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible to participate

Administrative

  • Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submission of the signed contract including the completed appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria; open house model with equal terms for all.

Buyer

Location

München, DEU

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open House Discount Agreement Erythropoietin alfa

Single lot covering the active substance Erythropoietin alfa. All interested pharmaceutical companies that meet the eligibility criteria can conclude the same discount agreement. The contract can be concluded at any time during the term, latest by 3 July 2027. Submission must be via the communication area of the dtvp portal (not the offer area) or by post with specific deadlines.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Aug 2025 - Aug 2027

Category

Pharmaceutical products

Award Criteria

No award criteria; open house model with equal terms for all.

Deadline

Deadline Jul 03, 2027

Procurement Details

Publication date
13 Jul 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
458024-2025

Documents (2)

Similar tenders